RESPONSE: A randomized, open label, phase III study of INC424 in polycythemia vera (PV) patients resistant to or intolerant of hydroxyurea (HU).
S. Verstovsek
Research Funding - AstraZeneca; Bristol-Myers Squibb; Celgene; Geron; Incyte; Lilly; Roche; S*Bio
J. Kiladjian
Consultant or Advisory Role - Novartis
R. J. Waltzman
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
V. Sandor
Employment or Leadership Position - Incyte
Stock Ownership - Incyte
J. Lukawy
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
W. M. Garrett
Employment or Leadership Position - Incyte
Stock Ownership - Incyte
K. Malek
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
R. M. Huber
Employment or Leadership Position - Incyte
Stock Ownership - Incyte
A. M. Vannucchi
Consultant or Advisory Role - Novartis